North America held the largest share of the global ADHD therapeutics market in 2022. In the region, the US held the largest ADHD therapeutics market share in 2022 and is estimated to continue its dominance from 2022 to 2030. The US has a high prevalence of ADHD, which propels the ADHD therapeutics market growth. According to Cingulate, ~6.4 million children and adolescents between 4 and 17 years of age were diagnosed with attention-deficit hyperactivity disorder (ADHD) in 2022. Among them, over 80% of this group received treatment, and about 65% have experienced symptoms of ADHD beginning from childhood that persisted into adulthood. Improved patient affordability, favorable reimbursement policies, and increased awareness of current drugs further drive the market.
Asia Pacific is the fastest-growing market for ADHD therapeutics owing to the presence of key players in the region and several strategic initiatives undertaken to develop and market new products. For example, in June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. reported positive results from its two six-week phase 3 clinical trials that assessed the effectiveness, safety, and tolerability of oral centanafadine. Centanafadine is a new experimental drug designed to treat adult patients diagnosed with ADHD. The company also planned to study the effects of centanafadine in children with ADHD and discuss the next steps with the US Food and Drug Administration.
Rising Emphasis on Research and Development to Develop ADHD Therapeutics Drives ADHD Therapeutics Market Growth
The market for ADHD therapeutics is expected to grow due to continuous developments in medical treatments, an increase in neuroscience research projects, and a rise in public awareness about mental illnesses. Growing awareness among patients, caregivers, and healthcare professionals about the impact of ADHD on daily functioning has led to an increased willingness to seek effective therapeutic interventions. The rising number of people suffering from various mental health disorders, including ADHD, has drawn the attention of governments worldwide, prompting them to take action. Biotechnology and pharmaceutical companies also focus on creating innovative treatments for ADHD. According to Regional Development Australia, in July 2021, the New South Wales (NSW) government contributed US$ 1.8 million to the ADHD pilot program for 2021–2022, with a total investment of US$ 7.7 million over four years to trial a new model of care and management for children with behavioral issues, including ADHD.
ADHD Therapeutics Market: Segmental Overview
The ADHD therapeutics market, by drug type, is bifurcated into stimulant and non-stimulant drugs. The stimulant drugs segment held a larger market share in 2022 and is anticipated to register a higher CAGR during 2022–2030. The ADHD therapeutics market, by age group, is segmented into pediatric, adolescent, and adult. The adult segment held the largest market share in 2022. The adolescent segment is anticipated to register the highest CAGR from 2022 to 2030. The ADHD therapeutics market, by distribution channel, is segmented into hospital pharmacies, retail pharmacies, and e-commerce. In 2022, the hospital pharmacies segment held the largest market share and is anticipated to register the highest CAGR during 2022–2030. Geographically, the ADHD therapeutics market is segmented into North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Spain, and the Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
ADHD Therapeutics Market: Competitive Landscape and Key Developments
Amneal Pharmaceuticals, Inc.; Novartis AG, Pfizer, Inc.; Eli Lilly and Company; Noven Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Johnson and Johnson Services, Inc.; Corium Inc.; Adlon Therapeutics L.P; and Teva Pharmaceutical Industries Ltd. are key players profiled in the ADHD therapeutics market. These companies adopt product development strategies to meet growing customer demands, which allow them to maintain their brand name in the ADHD therapeutics market.
A few of the recent developments in the global ADHD therapeutics market are mentioned below:
- In September 2023, Cingulate Inc. announced results from its Phase 3 study of adult efficacy and safety of its lead candidate, CTx-1301 (dexmethylphenidate), for treating ADHD. The company utilizes Precision Timed Release (PTR), its patented drug delivery platform technology, to build and advance a pipeline of next-generation pharmaceutical products. The results were presented on September 8th at the 36th Annual Psych Congress in Nashville, TN.
- In March 2022, Noven Pharmaceuticals, Inc., a completely owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., received approval from the US Food and Drug Administration (FDA) for its XELSTRYM (dextroamphetamine) transdermal system, CII, for the treatment of ADHD in adults and pediatric patients aged 6 years and above.
- In July 2021, Corium, Inc. launched AZSTARYS. This innovative medication combines Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) in the US for symptomatic treatment in patients 6 years and older. AZSTARYS got FDA approval in March 2021. It comprises a combination of two types of medication: 70% extended-release prodrug of d-MPH SDX (Schedule IV) and 30% immediate-release d-MPH (Schedule II).
- In April 2021, Supernus Pharmaceuticals, Inc. announced that the US FDA had approved a Qelbree (viloxazine extended-release capsules) to treat ADHD in patients aged 6–17.